The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Malignant Melanoma in Children and Adolescents Treated in Pediatric Oncology Centers: An Australian and New Zealand Children’s Oncology Group (ANZCHOG) Study
|
|---|---|
| Published in |
Frontiers in oncology, April 2021
|
| DOI | 10.3389/fonc.2021.660172 |
| Pubmed ID | |
| Authors |
Anne L. Ryan, Charlotte Burns, Aditya K. Gupta, Ruvishani Samarasekera, David S. Ziegler, Maria L. Kirby, Frank Alvaro, Peter Downie, Stephen J. Laughton, Siobhan Cross, Timothy Hassall, Geoff B. McCowage, Jordan R. Hansford, Rishi S. Kotecha, Nicholas G. Gottardo |
| Abstract |
Unlike adults, malignant melanoma in children and adolescents is rare. In adult melanoma, significant progress in understanding tumor biology and new treatments, including targeted therapies and immunotherapy have markedly improved overall survival. In sharp contrast, there is a paucity of data on the biology and clinical behavior of pediatric melanoma. We report a national case series of all pediatric and adolescent malignant melanoma presenting to ANZCHOG Childhood Cancer Centers in Australia and New Zealand. A retrospective, descriptive, multi-center study was undertaken to identify patients less than 18 years of age treated for cutaneous malignant melanoma over a twenty-year period (1994 to 2014). Data on clinical characteristics, histopathology, and extent of disease, treatment and follow-up are described. A total of 37 cases of malignant melanoma were identified from all of the Australasian tertiary Childhood Cancer Centers. The median age was 10 years (range 1 month - 17 years). Clinically, the most common type of lesion was pigmented, occurring in sixteen (57%) patients, whilst amelanotic was seen in 7 patients (25%). In 11 (27.9%) the Breslow thickness was greater than 4mm. A total of 11 (29.7%) patients relapsed and 90% of these died of disease. Five-year event free survival (EFS) and overall survival were 63.2 (95% CI: 40.6 - 79.1) and 67.7% (95% CI: 45.1 - 82.6) respectively. Our data confirms that melanoma is a rare presentation of cancer to tertiary Australasian Childhood Cancer Centers with only 37 cases identified over two decades. Notably, melanoma managed in Childhood Cancer Centers is frequently at an advanced stage, with a high percentage of patients relapsing and the majority of these patients who relapsed died of disease. This study confirms previous clinical and prognostic information to support the early multidisciplinary management in Childhood Cancer Centers, in conjunction with expert adult melanoma centers, of this rare and challenging patient group. |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Australia | 1 | 20% |
| Unknown | 4 | 80% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 5 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 24 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 24 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 3 | 13% |
| Student > Postgraduate | 2 | 8% |
| Student > Bachelor | 2 | 8% |
| Student > Doctoral Student | 1 | 4% |
| Lecturer | 1 | 4% |
| Other | 0 | 0% |
| Unknown | 15 | 63% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 7 | 29% |
| Agricultural and Biological Sciences | 2 | 8% |
| Physics and Astronomy | 1 | 4% |
| Design | 1 | 4% |
| Unknown | 13 | 54% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 October 2022.
All research outputs
#15,543,178
of 26,314,361 outputs
Outputs from Frontiers in oncology
#4,390
of 22,971 outputs
Outputs of similar age
#222,446
of 459,011 outputs
Outputs of similar age from Frontiers in oncology
#230
of 1,238 outputs
Altmetric has tracked 26,314,361 research outputs across all sources so far. This one is in the 40th percentile – i.e., 40% of other outputs scored the same or lower than it.
So far Altmetric has tracked 22,971 research outputs from this source. They receive a mean Attention Score of 3.2. This one has done well, scoring higher than 79% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 459,011 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.
We're also able to compare this research output to 1,238 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.